COST-EFFECTIVENESS ANALYSIS OF CRIZOTINIB VERSUS CHEMOTERAPY FOR FIRST LINE TREATMENT OF NONSMALL CELL LUNG CANCER ALK plus , FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVE

被引：0
|
作者：
Ferreira, P. [1 ]
Senna, T. [1 ]
Sebastiao, M. [1 ]
Alexandre, R. F. [1 ]
Almeida, P. [1 ]
机构：
[1] Pfizer, Sao Paulo, SP, Brazil
来源：
VALUE IN HEALTH | 2023年 / 26卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE52
引用
收藏
页码：S68 / S69
页数：2
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
    Zhou, Kexun
    Shu, Pei
    Zheng, Hanrui
    Li, Qiu
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [22] COST-EFFECTIVENESS OF THE INITIAL TREATMENT OF VENOUS THROMBOEMBOLISM FROM THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM PERSPECTIVE
    Alexandre, R. F.
    Squiassi, H. B.
    Santana, C. F.
    Nascimento, R.
    Lucchetta, R.
    Riveros, B. S.
    Pedro, G. O.
    Nita, M. E.
    VALUE IN HEALTH, 2017, 20 (05) : A29 - A29
  • [23] Cost-effectiveness analysis of alectinib versus crizotinib in first-line treatment of anaplastic lymphoma kinase-positive advanced non-small cell lung cancer
    Ravasio, R.
    Tiseo, M.
    Pradelli, L.
    Bellone, M.
    Gervasi, A.
    Coffani, M.
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2019,
  • [24] Eltrombopag as first-line treatment in severe aplastic anemia: a cost-effectiveness analysis from the Brazilian public healthcare system perspective (vol 43, pg S1, 2021)
    Salvino, M. A.
    Bonfim, C.
    Calado, R. T.
    Kim, H.
    Bertinato, J. F.
    Scheinberg, P.
    HEMATOLOGY TRANSFUSION AND CELL THERAPY, 2022, 44 (02) : 1 - 1
  • [25] COST-EFFECTIVENESS ANALYSIS AND BUDGET IMPACT OF CONCOR® AM VERSUS BISOPROLOL PLUS AMLODIPINE IN SYSTEMIC ARTERIAL HYPERTENSION TREATMENT, FROM THE PERSPECTIVE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM
    Fujii, R. K.
    Restrepo, M.
    Fernandes, R. A.
    Haas, L.
    Pepe, C.
    Junqueira, M.
    VALUE IN HEALTH, 2015, 18 (03) : A138 - A138
  • [26] Cost-Effectiveness Analysis of Durvalumab Plus Chemotherapy in the First-Line Treatment of Extensive-Stage Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Li, Shuosha
    Zhu, Youwen
    Shi, Yin
    Liao, Mengting
    Liu, Jin
    Tian, Xu
    Liu, Aiting
    Huang, Jin
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (10): : 1141 - +
  • [27] COST-EFFECTIVENESS OF PEMBROLIZUMAB plus AXITINIB VERSUS NIVOLUMAB plus IPILIMUMAB AS FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA IN THE PRIVATE HEALTHCARE SYSTEM IN BRAZIL
    Garmatter, L. P. Leonart
    Berlinski, F.
    Rego, M. A. D. C.
    Bastos, D. A.
    Soares, A.
    Kater, F. R.
    Nunes, A. A.
    Santos, M.
    Riveros, B. Salgado
    VALUE IN HEALTH, 2023, 26 (06) : S149 - S150
  • [28] COST-EFFECTIVENESS OF EML4-ALK FUSION TESTING AND FIRST-LINE CRIZOTINIB TREATMENT FOR PATIENTS WITH ADVANCED ALK POSITIVE NON-SMALL CELL LUNG CANCER IN A PUBLICLY FUNDED SYSTEM (ONTARIO, CANADA)
    Djalalov, S.
    Beca, J.
    Hoch, J. S.
    Krahn, M. D.
    Tsao, M. S.
    Cutz, J. C.
    Leighl, N.
    VALUE IN HEALTH, 2013, 16 (07) : A410 - A410
  • [29] Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive small cell lung cancer in China.
    Li, Lingyu
    Wang, Hong
    Li, Wenqian
    Cui, Jiuwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [30] Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first line treatment of extensive-stage small-cell lung cancer
    Zhou, Kexun
    Zhou, Jing
    Huang, Jiaxing
    Zhang, Nan
    Bai, Liangliang
    Yang, Yu
    Li, Qiu
    LUNG CANCER, 2019, 130 : 1 - 4
12345